|
May 22, 2026
|
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
|
|
|
May 12, 2026
|
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
|
|
|
Apr 30, 2026
|
AC Immune First Quarter 2026 Financial and Corporate Updates
|
|
|
Apr 30, 2026
|
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
|
|
|
Apr 07, 2026
|
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
|
|
|
Mar 19, 2026
|
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
|
|
|
Mar 13, 2026
|
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
|
|
|
Mar 05, 2026
|
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
|
|
|
Feb 24, 2026
|
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
|
|